← All trials
NCT05153343
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 6, 2021
- Primary completion
- Dec 29, 2022
- Completion date
- Feb 28, 2023
- First posted
- Dec 10, 2021
- Last posted
- Dec 10, 2021
- Enrollment
- 31
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of ChinaLead sponsor
- Sichuan UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.